1. Home
  2. EDSA vs VCIG Comparison

EDSA vs VCIG Comparison

Compare EDSA & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • VCIG
  • Stock Information
  • Founded
  • EDSA 2015
  • VCIG 2013
  • Country
  • EDSA Canada
  • VCIG Malaysia
  • Employees
  • EDSA N/A
  • VCIG N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • VCIG Diversified Commercial Services
  • Sector
  • EDSA Health Care
  • VCIG Consumer Discretionary
  • Exchange
  • EDSA Nasdaq
  • VCIG Nasdaq
  • Market Cap
  • EDSA 6.1M
  • VCIG 5.8M
  • IPO Year
  • EDSA N/A
  • VCIG 2023
  • Fundamental
  • Price
  • EDSA $1.89
  • VCIG $1.57
  • Analyst Decision
  • EDSA Strong Buy
  • VCIG
  • Analyst Count
  • EDSA 1
  • VCIG 0
  • Target Price
  • EDSA $21.00
  • VCIG N/A
  • AVG Volume (30 Days)
  • EDSA 31.2K
  • VCIG 19.8M
  • Earning Date
  • EDSA 02-07-2025
  • VCIG 02-10-2025
  • Dividend Yield
  • EDSA N/A
  • VCIG 30.64%
  • EPS Growth
  • EDSA N/A
  • VCIG N/A
  • EPS
  • EDSA N/A
  • VCIG 7.82
  • Revenue
  • EDSA N/A
  • VCIG $23,548,256.00
  • Revenue This Year
  • EDSA N/A
  • VCIG N/A
  • Revenue Next Year
  • EDSA N/A
  • VCIG N/A
  • P/E Ratio
  • EDSA N/A
  • VCIG $0.21
  • Revenue Growth
  • EDSA N/A
  • VCIG 89.38
  • 52 Week Low
  • EDSA $1.69
  • VCIG $1.38
  • 52 Week High
  • EDSA $5.99
  • VCIG $115.64
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 37.11
  • VCIG 38.52
  • Support Level
  • EDSA $1.73
  • VCIG $1.51
  • Resistance Level
  • EDSA $2.55
  • VCIG $2.24
  • Average True Range (ATR)
  • EDSA 0.18
  • VCIG 0.58
  • MACD
  • EDSA 0.03
  • VCIG -0.01
  • Stochastic Oscillator
  • EDSA 25.58
  • VCIG 0.51

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development solution consultancy. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology Consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment which focuses on listing solutions, investor relations, and boardroom strategies consultancy. It has established a diverse local and international clientele, providing them with its services in both local and cross-border listings. Its role begins with pre-listing diagnosis and planning to the finalization of the entire listing process.

Share on Social Networks: